Moderate to severe psoriasis
Conditions
Interventions
Short-acting biological therapy group:None
Long-acting biological agent treatment group:None
Sponsors
The First Affiliated Hospital of Guangxi Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age >= 18 years, any gender, and a confirmed diagnosis of moderate-to-severe plaque psoriasis; 2. Have received treatment with usulumab injection or secukinumab injection, or have switched from another biologic agent; 3. Voluntarily sign a written informed consent form and be able to comply with the requirements of the study protocol.
Exclusion criteria
Exclusion criteria: 1. Presence of an active infection (e.g., active tuberculosis, HBV/HCV/HIV infection); 2. History of malignant tumors (excluding basal cell carcinoma or squamous cell carcinoma of the skin, provided that the condition has been cured for >=5 years); 3. People who are allergic to biologics and their excipients; 4. Those who have received a live vaccine within the past 3 months or plan to receive one; 5. Researchers determined that the participant was not eligible for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incremental Cost-Utility Ratio (ICUR); | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality-Adjusted Life Year (QALY);The proportion of cases where the DLQI score improved by >=50% compared to the baseline value;Incidence of serious adverse events (SAE);Changes in the number of outpatient visits, hospitalizations, and drug retention rates;26/5000 Per capita annual direct medical costs (including drug expenses, examination fees, hospitalization fees, and outpatient fees);Continuous remission rate;The response rate of PASI75 and the changes from the baseline;Frequency of recurrence; | — |
Countries
China
Contacts
Public ContactHongliang Zhang
The First Affiliated Hospital of Guangxi Medical University
Outcome results
None listed